Evidence map›Paper›PMID 41987507›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2026

Biomarkers of Leucine-Rich Repeat Kinase 2 (LRRK2) and Lysosomal Dysfunction in Progressive Supranuclear Palsy.

Louise-Kristine Nielsen, Joshua L I Frost, David P Vaughan, Raquel Real, Riona Fumi, Marte Theilmann Jensen, Megan Hodgson, Eleanor J Stafford, Lesley Wu, Olaf Ansorge and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Louise-Kristine NielsenMedical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
Joshua L I FrostDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0009-0002-9729-0077
David P VaughanDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Raquel RealDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Riona FumiDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Marte Theilmann JensenDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Megan HodgsonDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Eleanor J StaffordDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Lesley WuDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Olaf AnsorgeNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Annelies QuaegebeurDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Kieren S J AllinsonDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Thomas T WarnerReta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.
Zane JaunmuktaneReta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0000-0001-7738-8881
Anjum MisbahuddinDepartment of Neurology, Queen's Hospital, Romford, UK.
P Nigel LeighDepartment of Neuroscience, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, UK.
Boyd C P GhoshWessex Neurological Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.
Kailash P BhatiaDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Alistair ChurchDepartment of Neurology, Royal Gwent Hospital, Newport, UK.
Christopher KobyleckiDepartment of Neurology, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-7797-0756
Michele T M HuNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
James B RoweDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust and MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0001-7216-8679
Alan A ShomoNeurodegenerative Diseases Research Unit, Biogen, Cambridge, Massachusetts, USA.
Danielle L GrahamNeurodegenerative Diseases Research Unit, Biogen, Cambridge, Massachusetts, USA.
Omar S MabroukNeurodegenerative Diseases Research Unit, Biogen, Cambridge, Massachusetts, USA.
Huw R MorrisDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0000-0002-5473-3774
Esther M SammlerMedical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.ORCID https://orcid.org/0000-0003-3218-7116
Edwin JabbariDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0000-0001-6844-882X

Funding

CurePSP 681-2022/06Medical Research Council UKRI1388PSP Association PSPA2023/PROJECTGRANT001
6 · The paper itself

Abstract

backgroundCommon and rare genetic variants in leucine-rich repeat kinase 2 (LRRK2) have been linked with sporadic and familial Parkinson's disease (PD). Recently, we discovered that common genetic variation near the LRRK2 locus determined survival in progressive supranuclear palsy (PSP). Our study aimed to explore biomarkers of LRRK2 and lysosomal dysfunction in PSP.

methodsImmunoblotting was used to measure total LRRK2 and LRRK2-dependent Rab10 phosphorylation at the threonine 73 residue (pRab10

resultsA total of 61 PSP and 34 control participants were included. Total urine 22:6-BMP levels were higher in PSP versus control samples (P = 0.04) and correlated with CSF total LRRK2 levels (r = 0.49, P = 0.04). There were no group-level differences in monocyte and CSF levels of total LRRK2 and pRab10

conclusionsBiochemically defined lysosomal dysfunction is evident in PSP. Genetic and biochemical stratification may identify PSP patients that would benefit from LRRK2-targeting therapies. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2LysosomesSupranuclear Palsy, ProgressiveAgedBiomarkersFemaleGenotypeHumansMaleMiddle AgedMonocytesPhosphorylationrab GTP-Binding ProteinsBiomarkersLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanRab10 protein, humanrab GTP-Binding Proteins

Identifiers

PMID41987507
PMCPMC13387967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.